Skip to main content
ATRC logo

ATRC · AtriCure, Inc.

Track ATRC — free
$55.88 +0.57 (+1.02%)
Market Cap
$2.82B
Shares
50.92M
Volume · Nov 17 52.13K Avg daily vol (3M) 1.05M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$55.31 Open$57.00 Day$55.02–57.22 52W close$25.86–65.53 Avg vol 30d761K Short int4.9M · 9.6% of shares · 7.6d Short vol64% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 16, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 11
Investor event
BoxX Data and Updated Guidance

AtriCure updated 2026 revenue guidance to $606 to $610 million. BoxX is expected to be fully enrolled by the end of this year, with 30-day post-op AFib data planned for May of next year.

5 source passages
welcome Atricure to the 2026 Stiefel Healthcare Conference. the updated 2026 guidance you provided before getting into some more product-specific clinical data-oriented questions. Updated now to $606 to $610 million. BoxX has enrolled faster than expected. because we're going to be fully enrolled by the end of this year, we will be presenting the data on the post-op affibrate, that 30-day endpoint, in May of next year. Open the document at this passage
Nov 9
Investor event
Long-term targets include adjusted EBITDA margin north of 20 percent

Atricure targets double-digit revenue growth and adjusted EBITDA margin north of 20 percent while eyeing a 10 billion plus market and pursuing organic R&D.

2 source passages
Atricure continues to be a double-digit revenue grower, that we've got gross margin expansion, and that we believe very strongly that we would be an adjusted EBITDA margin north of 20 percent. Where we sit today, we are eyeing 10 billion plus, and I think still have designs on how we can expand and use kind of our power strengths, which are our ablation technologies Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 15.0% and net income reaches $4,064 thousand

AtriCure reported third-quarter revenue of $154,450 thousand, up 15.0%, and net income of $4,064 thousand versus a $267 thousand loss. In October 2026, FDA cleared the 30 mm AtriClip FLEX-Mini device.

Revenue $154.45M ▲ 15.0% Net income $4.06M Diluted EPS $0.08
Read from the MD&A section
5 source passages
Such statements are based largely upon current expectations of AtriCure. Worldwide revenue increased 15.0% (15.1% on a constant currency basis). | Revenue | 154,450 | 100.0% | 134,269 | 100.0% | | Net income (loss) | 4,064 | 2.6% | (267) | (0.2)% | In October 2026, we received FDA 510(k) clearance for the 30 mm AtriClip FLEX-Mini device. Open the document at this passage
Nov 3
Earnings call
15% revenue growth, adjusted EBITDA outlook raised

AtriCure reported third-quarter revenue of $154.5 million, up 15%, and raised 2026 adjusted EBITDA guidance to approximately $91 million to $94 million while expecting revenue of approximately $606 million to $610 million.

4 source passages
Third quarter worldwide revenue was $154.5 million, increasing 15% on a reported basis and 15.1% in constant currency compared with the third quarter of 2025. We now expect full year 2026 revenue of approximately $606 million to $610 million, representing annual growth of approximately 13.4% to 14.1% compared with 2025. We are reiterating our expectation of full-year net income and are raising our 2026 adjusted EBITDA outlook to approximately $91 million to $94 million. H-Recure's results may differ materially from those projected. Open the document at this passage
Nov 3
Current report 8-K
Third-quarter revenue rises 15.0%, adjusted EBITDA reaches $26.8 million

AtriCure reported third-quarter 2026 worldwide revenue of $154.5 million, up 15.0%, net income of $4.1 million and adjusted EBITDA of $26.8 million. Full-year 2026 revenue guidance is approximately $606 million to $610 million.

Financial results
3 source passages
Third Quarter 2026 worldwide revenue of $154.5 million, an increase of 15.0% year over year Profitability expansion in the Third Quarter 2026, with net income of $4.1 million and adjusted EBITDA of $26.8 million Full year 2026 revenue is now projected to be approximately $606 million to $610 million Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$589.80M
Trailing 12 months
Net income (TTM)
$14.88M
Trailing 12 months
Revenue growth YoY
+15.0%
Year over year
Operating margin
2.9%
Trailing 12 months
P / E (TTM)
189.5
Trailing earnings · reciprocal yield 0.5%
FCF yield
1.9%
TTM · current market cap
Return on invested capital
3.8%
Trailing 12 months
Net cash
$126.03M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.0%
Year over year · more shares
Price change (1Y)
+68.1%
Trailing year
Short interest
9.6%
Latest settlement · 7.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 3, 2026
Q3 FY26

TL;DR. AtriCure delivered 15.0% worldwide revenue growth, expanded profitability and gross margin, raised adjusted EBITDA guidance, and remained on track for BOXX-NoAF enrollment and a spring 2027 readout. Risks included declining minimally invasive ablation sales, hybrid-ablation and international headwinds, expected fourth-quarter gross-margin pressure, higher clinical R&D investment, and present and potential competition in appendage management.

Bullish
  • + Third-quarter worldwide revenue grew 15.0% year over year to $154.5 million.
  • + Third-quarter profitability expanded, with net income of $4.1 million and adjusted EBITDA of $26.8 million.
  • + Third-quarter gross margin increased 180 basis points to 77.3%.
  • + Management raised its 2026 adjusted EBITDA outlook to approximately $91 million to $94 million.
  • + The BOXX-NoAF trial remained on track to complete enrollment before year-end, with primary-endpoint data expected in spring 2027.
  • + Growth was broad-based across pain management, open ablation, and appendage management.
Bearish
  • − Minimally invasive ablation sales declined as hybrid procedures fell and physicians adopted PFA catheters.
  • − Management identified the U.S. hybrid ablation business and international markets as continuing headwinds, with no significant international recovery expected for the rest of 2026.
  • − Gross margin is expected to decline somewhat in the fourth quarter because of a full quarter of costs from the new manufacturing facility.
  • − Research and development expenses increased 20.6%, excluding the PFA milestone payment, reflecting substantial clinical investment from the BOXX NO-AF trial and incremental investment in new product development.
  • − Appendage management faces one competitor in the market, with potentially another competitor in the future.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 22.9 · elevated Equity put/call 0.73
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +41%
above
Price vs 50-day avg −4%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 74%
mid-range
Momentum
relative strength
Very Strong
1-month return 0%
trailing
6-month return +101%
trailing
YTD return +40%
this year
Relative strength +103%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $58 › 200d $39 — 50d above 200d
Institutional flow Accumulating
+12% holders QoQ · +79 funds added
Insider flow Distributing
Net -$889.6K over 90 days · 100% sells
Short interest Rising
9.60% of shares out · ▲ +0.1% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
283 holders — near 3-yr high, broad support
Squeeze score 76
high risk · 0–100
Fundamentals
Excellent
Revenue growth +15%
Y/Y
Gross margin 199%
contracting
EPS growth +75%
Y/Y
Free cash flow $48.3M
Valuation P/E 184.4
rich
Quant / Vol
risk profile
Very High
Volatility 47%
annualized · 1-yr
Max drawdown −39%
past year
ATR 4.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 6
Latest guidance · from the 8-K filed Jul 23, 2026
Revenue · Full year 2026 Raised $602M – $610M
May 5, 2026 $600M – $610M changed to Jul 23, 2026 $602M – $610M
prior FY $534.53M midpoint +13.4% Y/Y
Adjusted EBITDA · Full year 2026 Non-GAAP Raised $85M – $89M
May 5, 2026 $80M – $82M changed to Jul 23, 2026 $85M – $89M
Net income per share · Full year 2026 Raised $0.05 – $0.13
May 5, 2026 $0.00 – $0.04 changed to Jul 23, 2026 $0.05 – $0.13
prior FY $-0.24 midpoint +137.5% Y/Y
Adjusted earnings per share · Full year 2026 Non-GAAP $0.24 – $0.32
Previous outlook earlier release · from the 8-K filed May 5, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted earnings per share · Full year 2026 $0.00 – $0.04
Guided vs delivered · last 6 settled
Revenue full year 2024
guided $456M – $461M
$465.31M Beat +1.5%
Full year 2023 revenue full year 2023
guided $394M – $396M
$399.25M Beat +1.1%
Revenue Full year 2022
guided $323M – $333M
$330.38M In line
Revenue full year 2021
guided $270M – $275M
$274.33M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+41% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
74% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $58 › 200d $39 — 50d above 200d
Institutional flow Accumulating
+12% holders QoQ · +79 funds added
Insider flow Distributing
Net -$889.6K over 90 days · 100% sells
Short interest Rising
9.60% of shares out · ▲ +0.1% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
283 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $26 Now $55 · 74% Range high $66
vs 200-day avg +41% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Appendage management revenue $51.61M Three Months Ended June 30, 2026 filing —
Minimally invasive ablation revenue $6.03M Three Months Ended June 30, 2026 filing —
Open ablation revenue $40.89M Three Months Ended June 30, 2026 filing —
Pain management revenue $27.06M Three Months Ended June 30, 2026 filing —
Total International revenue $28.02M Three Months Ended June 30, 2026 filing —
Total United States revenue $125.59M Three Months Ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATRC
AtriCure, Inc.
this stock
$2.82B +39.8% +15.4% 184.4 9.6%
ISRG
Intuitive Surgical Inc
$151.74B -22.7% +20.5% 53.1 2.0%
BDX
Becton Dickinson & Co
$58.96B — +8.2% 95.8 3.0%
MDLN
Medline Inc.
$51.52B -6.7% +11.5% — 2.9%
ALC
Alcon Inc
$35.38B -6.6% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
283
% held
105.3%
Net QoQ
+1.3M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
261
View
Short & Settlement
Short Interest Rising
Shares short
4.9M
Days to cover
7.6d
Change
+3.4K sh
View
Short Volume
Short vol %
64%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
52
Value
$3.2K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
45.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$889.6K
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Sell
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Sep 29, 2026
View
Financials
Financials
Revenue (FY)
$534.5M
Net income (FY)
$-11.4M
EPS diluted
$-0.24
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 11, 2026
This year
19

AtriCure updated 2026 revenue guidance to $606 to $610 million. BoxX is expected to be fully enrolled by the end of this year, with 30-day post-op AFib data planned for May of next year.

View
Proposed Sales
Value
$143.4K
Shares
2.5K
Filed
Nov 6, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
AtriCure Reports Third Quarter 20…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
ATRC -4.3% -0.4% +101.5% -9.7% +39.8%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -2.6% +3.1% +102.9% -7.6% +31.3%
Key facts CIK 1323885 CUSIP 04963C209 13F (30d) 287 filings 265 filers Visit website Investor relations